Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AERINASDAQ:IBRXNASDAQ:IMVTNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAERIAerie Pharmaceuticals$15.25$15.23$4.81▼$15.37$753.61M-0.06974,748 shs600 shsIBRXImmunityBio$2.87+1.1%$2.67$1.83▼$7.63$2.51B0.146.10 million shs9.12 million shsIMVTImmunovant$15.80-0.4%$15.07$12.72▼$34.47$2.71B0.611.22 million shs1.91 million shsSRRKScholar Rock$34.04-6.3%$31.65$6.76▼$46.98$3.45B0.281.30 million shs3.22 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAERIAerie Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IBRXImmunityBio0.00%-10.97%-2.07%+4.80%-54.41%IMVTImmunovant0.00%-0.50%+5.73%-19.25%-39.44%SRRKScholar Rock0.00%+9.00%+15.16%+9.89%+327.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAERIAerie PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIBRXImmunityBio2.3569 of 5 stars3.62.00.00.02.01.70.6IMVTImmunovant0.9331 of 5 stars3.50.00.00.00.01.70.0SRRKScholar Rock4.4191 of 5 stars3.62.00.04.43.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAERIAerie Pharmaceuticals 0.00N/AN/AN/AIBRXImmunityBio 3.20Buy$12.25326.83% UpsideIMVTImmunovant 2.90Moderate Buy$38.33142.62% UpsideSRRKScholar Rock 3.14Buy$42.6725.34% UpsideCurrent Analyst Ratings BreakdownLatest AERI, SRRK, IMVT, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/28/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/5/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/28/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAERIAerie Pharmaceuticals$194.13M3.88N/AN/A($3.32) per share-4.59IBRXImmunityBio$14.74M171.85N/AN/A($0.57) per share-5.04IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASRRKScholar Rock$33.19M97.38N/AN/A$3.94 per share8.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAERIAerie Pharmaceuticals-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/AIBRXImmunityBio-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest AERI, SRRK, IMVT, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAERIAerie PharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAERIAerie PharmaceuticalsN/A2.271.92IBRXImmunityBioN/A2.222.05IMVTImmunovantN/A11.1611.16SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAERIAerie Pharmaceuticals95.94%IBRXImmunityBio8.58%IMVTImmunovant47.08%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipAERIAerie Pharmaceuticals4.44%IBRXImmunityBio76.79%IMVTImmunovant5.90%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAERIAerie Pharmaceuticals37649.42 million47.22 millionOptionableIBRXImmunityBio590882.62 million204.86 millionOptionableIMVTImmunovant120170.92 million160.84 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionableAERI, SRRK, IMVT, and IBRX HeadlinesRecent News About These CompaniesScholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?June 20 at 12:28 PM | marketbeat.comScholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug TrialJune 19 at 2:18 PM | insidermonkey.comScholar Rock data show promise for muscle-preserving combo with ZepboundJune 19 at 6:07 AM | thepharmaletter.comScholar Rock (NASDAQ:SRRK) Given Outperform Rating at WedbushJune 19 at 2:58 AM | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushJune 18 at 10:11 PM | marketbeat.comScholar Rock says its drug preserved lean mass in patients taking ZepoundJune 18 at 8:05 PM | statnews.comScholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody ComboJune 18 at 8:05 PM | biospace.comScholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trialJune 18 at 8:05 PM | fiercebiotech.comScholar Rock stock soars after drug shows promise in preserving lean mass during weight lossJune 18 at 8:05 PM | au.investing.comScholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drugJune 18 at 8:05 PM | msn.comScholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial ResultsJune 18 at 8:05 PM | msn.comScholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight LossJune 18 at 8:05 PM | msn.comWhy Scholar Rock Shares Are Soaring TodayJune 18 at 3:03 PM | fool.comScholar Rock (NASDAQ:SRRK) Shares Gap Up - What's Next?June 18 at 1:18 PM | marketbeat.comScholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss StudyJune 18 at 10:47 AM | benzinga.comScholar Rock Shares Jump on Positive Results from Weight Loss TrialJune 18 at 8:15 AM | marketwatch.comScholar Rock's drug helps preserve lean mass in mid-stage trialJune 18 at 7:12 AM | reuters.comGAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)June 17 at 3:14 AM | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | businesswire.comCalifornia State Teachers Retirement System Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)June 7, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Trading 5.9% Higher - Here's WhyJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAERI, SRRK, IMVT, and IBRX Company DescriptionsAerie Pharmaceuticals NASDAQ:AERIAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.ImmunityBio NASDAQ:IBRX$2.87 +0.03 (+1.06%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.01 (+0.52%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$15.80 -0.06 (-0.38%) Closing price 04:00 PM EasternExtended Trading$15.80 0.00 (0.00%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Scholar Rock NASDAQ:SRRK$34.04 -2.28 (-6.28%) Closing price 04:00 PM EasternExtended Trading$33.91 -0.13 (-0.38%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
